IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 22.58

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-12 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.82 (+1.30%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.84 (+1.27%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+1.50 (+1.42%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+0.21 (+0.23%)

USD 0.21B
SBIO ALPS Medical Breakthroughs ETF

-0.52 (-1.66%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+2.03 (+2.18%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.03 (+0.11%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.49 (+0.81%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.58 (-2.56%)

USD 8.55M
IHF iShares U.S. Healthcare Provid..

+1.41 (+2.87%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.22% 33% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.22% 33% F 62% D
Trailing 12 Months  
Capital Gain -2.84% 20% F 31% F
Dividend Return 0.48% 38% F 5% F
Total Return -2.36% 19% F 23% F
Trailing 5 Years  
Capital Gain -24.21% 10% F 25% F
Dividend Return 3.07% 53% F 8% B-
Total Return -21.13% 14% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -4.74% 5% F 13% F
Dividend Return -4.21% 5% F 10% F
Total Return 0.53% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 32.72% 14% F 32% F
Risk Adjusted Return -12.86% 5% F 14% F
Market Capitalization 0.12B 60% D- 30% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.